Candriam S.C.A. Sells 13,701 Shares of argenex SE $ARGX

Candriam S.C.A. reduced its stake in shares of argenex SE (NASDAQ:ARGX) by 17.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,419 shares of the company’s stock after selling 13,701 shares during the quarter. Candriam S.C.A. owned about 0.11% of argenex worth $63,923,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Mather Group LLC. lifted its position in argenex by 19.1% in the 3rd quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after purchasing an additional 13 shares during the last quarter. Farther Finance Advisors LLC grew its position in argenex by 3.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock worth $363,000 after purchasing an additional 13 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of argenex by 2.7% in the third quarter. Oppenheimer & Co. Inc. now owns 500 shares of the company’s stock valued at $479,000 after purchasing an additional 13 shares during the period. NewEdge Advisors LLC raised its holdings in shares of argenex by 2.8% during the first quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after buying an additional 14 shares during the last quarter. Finally, Nvwm LLC boosted its position in shares of argenex by 1.3% during the third quarter. Nvwm LLC now owns 1,538 shares of the company’s stock worth $1,475,000 after buying an additional 20 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Up 3.6%

Shares of argenex stock opened at $927.21 on Friday. The firm has a market cap of $58.31 billion, a price-to-earnings ratio of 32.35, a price-to-earnings-growth ratio of 0.86 and a beta of 0.48. The business has a fifty day simple moving average of $930.66 and a 200-day simple moving average of $857.30. argenex SE has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75.

argenex (NASDAQ:ARGX) last released its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Analysts anticipate that argenex SE will post 28.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ARGX shares. Citigroup decreased their price objective on argenex from $1,301.00 to $1,232.00 and set a “buy” rating for the company in a report on Tuesday, October 27th. Wedbush cut their target price on argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research note on Thursday, October 8th. Guggenheim reduced their price target on argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a research report on Friday, October 23rd. UBS Group raised argenex from a “neutral” rating to a “buy” rating and increased their price target for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Finally, Royal Bank Of Canada lowered their price target on argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,158.76.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs.

Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy.